Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia

Inclusion Criteria

• •Be male or female aged 18 to 55 years (inclusive).
• •Have a DSM-5 diagnosis of schizophrenia or schizoaffective disorder confirmed by medical records. Duration of illness must be ≥ 1year.
• •Be clinically stable for at least two months (i.e., has no more than a "moderately severe" severity rating on the following BPRS items: hallucination, unusual thought content and conceptual disorganization.
• •Have not had a psychiatric hospitalization in the two months prior to screening.
• •Be taking any 1st generation antipsychotic prescribed in the absence of a concomitant anticholinergic or 2nd generation antipsychotic and minimal extrapyramidal symptoms
• •Have a Simpson-Angus Score (SAS) \< 6
• •Be on current medication regimen for at least six weeks before screening at stable dose and frequency for at least 30 days before screening.
• •Be in good general health and expected to complete the clinical study as designed.
• •Subjects of childbearing potential must agree to use two forms of non-hormonal contraception (dual contraception) consistently during the screening and treatment periods of the trial, and for 30 days after the final dose of the study medications.
• •Females of child-bearing potential must have a negative urine pregnancy test at baseline. This may also be done at subsequent visits if subject reports possibility of pregnancy.
• •Have a negative urine drug screen at screening. This may be repeated at the discretion of the primary investigator.
• •Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.
• •Be capable of providing informed consent and have voluntarily provided informed consent.